SHANMU Biotech Secures Tens of Millions in Pre-A+ Funding to Accelerate AI-Powered Home Healthcare Robot Commercialization

SHANMU (Shenzhen) Biotechnology Co., Ltd. (hereinafter referred to as “SHANMU”) Announces Completion of a New Pre-A+ Financing Round Worth Tens of Millions This Year. This round of financing was led by ChangThe Zhixing No. 1 Fund under Gan Jie, Professor of Finance and former Associate Dean at Jiangshang Business School, Co-founder of Xbotpark, and Founder of Zhixing Research Institute; Gao Bingqiang, Founding Dean of the School of Engineering and Chair Professor of Engineering at the Hong Kong University of Science and Technology (HKUST); Zhang Haixia, Professor at the School of Electronics Engineering and Computer Science, Peking University, and her ICANX Fund; and Green Pine CapitalJoint Investment,Gengxin CapitalServed as the long-term exclusive financial advisor.The funds will be used to optimize the shareholder structure, drive mass production of products, and prepare for delivery to consumer markets both domestically and internationally, thereby further accelerating the deployment of “AI-powered home healthcare robots.”

This investment consortium brings together top-tier talents from academia and industry: a “Professors’ Group” comprising Professor Gan Jie (Professor of Finance and former Associate Dean at Cheung Kong Graduate School of Business, Co-founder of XbotPark, and Founder of Zhixing Research Institute), Professor Gao Bingqiang (Professor at The Hong Kong University of Science and Technology [HKUST], Founding Dean of the School of Engineering, HKUST Fellow in Engineering, and a globally renowned expert in microelectronics), and Professor Zhang Haixia (Expert in micro- and nano-fields at Peking University and Founder of the ICAN Competition). This group wields significant influence in the venture capital sector through its deeply integrated model of industry-academia-research collaboration. Professor Gan Jie has achieved notable success in corporate finance, including receiving the Brennan Best Paper Award. As a global expert in microelectronics, Professor Gao Bingqiang has founded multiple chip companies and successfully invested in numerous projects. Professor Zhang Haixia has led more than 20 national key scientific research projects and holds 30 Chinese invention patents.

As a leading technology investment firm in China, Green Pine Capital manages assets worth tens of billions of RMB, focusing on hard-tech sectors such as digital technology and precision medicine. It has invested in star enterprises including SenseTime, BGI Genomics, and DJI Innovations.

SHANMU has once again secured investment from the “Professor Group Fund” and venture capital firms, accelerating the implementation of its “home healthcare gateway.”

SHANMU, founded in London, UK in 2021, is a global leader in the research and development of home medical robots. Its core product, the “Sensing Series,” is a fully automated medical robot the size of a computer mouse. Integrating microfluidic chipsets, multispectral systems, and AI-powered vertical pathology models, it has become the world’s most miniaturized medical-grade biochemical analyzer, with detection sensitivity, precision, and specificity consistent with the standards of hospital-grade equipment worth millions.

This product revolutionizes traditional healthcare scenarios—Household users can achieve absolute quantitative analysis of 10+ metabolites and proteins through routine urination.The SHANMU AI Agent can automatically retrieve multi-dimensional user data, including dietary habits, daily routines, and medical history, and integrate these with continuous biomarker test results to provide disease prediction, auxiliary diagnosis, comorbidity analysis, and medication recommendations via a mobile app within 10 minutes.

SHANMU's AI agent is aAI Family Doctor Spanning the User's Entire LifecycleBy dynamically accumulating multi-dimensional, continuous data, the system will build a “personalized health digital twin” for each user, fundamentally transforming the traditional model of “seeking medical care only when ill.” This empowers households with a “private physician who best understands their physiological status,” truly realizing a paradigm shift from disease treatment to proactive health management.

Industry insiders pointed out that this financing round is not only a recognition of SHANMU’s technological strength by capital markets, but also marks the further activation of potential in the “AI + Home Healthcare” sector. As population aging intensifies and demand for health management upgrades, SHANMU has"Miniaturized Devices + AI Diagnosis + Full-Cycle Management"This model is poised to become the core entry point for home healthcare in the AGI era, paving a new path for the trillion-yuan family health market.